Related Experiment Video
Updated: May 16, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Clots kill: hematologic pharmacology for ST-segment elevation myocardial infarction.
1Queen of the Valley Medical Center in Napa, California 94558, USA. stacyhealy@sbcglobal.net
Critical Care Nurse
|December 4, 2012
Summary
Hematologic drugs are crucial for reducing complications from acute coronary syndromes. This review details fibrinolytic, thrombin inhibitor, and antiplatelet agents, emphasizing their importance through a case study.
Area of Science:
- Pharmacology
- Hematology
- Cardiology
Background:
- Acute coronary syndromes (ACS) are associated with significant morbidity and mortality.
- Hematologic medications are vital in managing ACS.
- Understanding the mechanisms of these drugs is essential for effective treatment.
Observation:
- This review describes the pharmacology of key drug classes used in ACS.
- Included are fibrinolytic agents, thrombin inhibitors, and antiplatelet agents.
- A case study of ST-segment elevation myocardial infarction (STEMI) illustrates their application.
Findings:
- Fibrinolytic agents promote clot breakdown.
- Thrombin inhibitors prevent blood clot formation by targeting thrombin.
- Antiplatelet agents inhibit platelet aggregation, a key step in thrombosis.
Implications:
- Appropriate use of hematologic drugs can significantly improve ACS patient outcomes.
- Pharmacological interventions targeting the hematologic system are central to ACS management.
- Case studies reinforce the clinical relevance of these drug classes in critical cardiac events.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...